About Us

Alzheimer’s Drug Discovery Foundation (ADDF)

ADDF is a nonprofit organization founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies with a mission to fund scientists and companies developing innovative Alzheimer’s disease drug research and development worldwide. ADDF has invested >$160M in over 650 discovery, preclinical development, and early-phase clinical trial programs in academic institutions and biotechnology companies in 18 countries. For more information, please visit www.alzdiscovery.org.

MRL Ventures Fund

MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture fund of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.

From its headquarters in Cambridge, M.A., USA, the MRLV team invests globally in early-stage innovative therapeutics companies that are developing transformative medicines in any therapeutic area using any modality.  The MRLV team of experienced life-sciences venture capital professionals is committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease. For more information, please visit: www.mrlv.com.

Dolby Family Ventures

Dolby Family Ventures is an early stage venture firm focused on building great technology companies and advancing scientific discovery through investments in innovation. The fund portfolio includes biotech platforms and tools, diagnostics, as well as a host of novel therapeutic approaches to Alzheimer’s disease. The firm engages with new biopharma programs prior to Phase I human clinical trials, with a focus on optimizing drug candidates, launching successful clinical trials, and building strategic relationships with investment syndicates and partners in the Pharmaceutical industry to help find a cure to Alzheimer’s disease. To learn more, please visit www.dolbyventures.com.

Dementia Discovery Fund (DDF)

The DDF is a venture capital fund which invests in projects and companies to discover and develop novel, effective, disease-modifying therapeutics for dementia. Seven leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK’s Department of Health and Social Care, and charity Alzheimer’s Research UK have invested in the DDF to date. The DDF is managed by SV Health Managers LLP, where a dedicated team of neuroscientists and experts work alongside a scientific advisory board – comprised of representatives from the strategic investors – to identify and evaluate novel approaches for the treatment of dementia. To learn more, please visit www.theddfund.com.

Foundation For a Better World

Foundation For a Better World funds a wide array of initiatives supporting medical research, education and global development with a specific focus on advancing medical research that seeks to treat and cure neurodegenerative diseases. To learn more, please visit www.forabetterworldfoundation.org.

Lilly Ventures

Lilly Ventures is the venture capital arm of pharmaceutical company, Eli Lilly and Company.  Lilly Ventures looks at early to expansion stage investments.  Lilly Ventures has committed over $2 billion to biotech over the last 20 years through venture investing and specifically targets opportunities in biotechnology, healthcare IT, and medical technology.  For more information, visit www.lilly.com/partners.

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in the
innovators behind the miracles of science who are passionate about improving human health.
Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically
investing in early–stage transformational science and technology, when companies are too early
to partner with or acquire. For more information, visit www.sanofiventures.com.

SV Health Investors

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.7 billion in assets under management and a truly transatlantic presence with offices in London and Boston, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs. For more information, please visit www.svhealthinvestors.com.

The SV7 Impact Medicine Fund (IMF) is SV’s first fund focused solely on Biotech investments. The Fund’s mission is to turn scientific breakthroughs into successful biotech companies producing high impact precision medicine drugs for poorly treated diseases. As with SV’s predecessor funds, the IMF will maximize the Fund’s potential to transform healthcare by working closely with its cutting-edge portfolio companies as trusted advisers and partners and by acting as entrepreneurs who can create and build breakthrough companies and treatments.